225 related articles for article (PubMed ID: 10965493)
1. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo.
Leland P; Taguchi J; Husain SR; Kreitman RJ; Pastan I; Puri RK
Mol Med; 2000 Mar; 6(3):165-78. PubMed ID: 10965493
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
Beseth BD; Cameron RB; Leland P; You L; Varricchio F; Kreitman RJ; Maki RA; Jablons DM; Husain SR; Puri RK
Ann Thorac Surg; 2004 Aug; 78(2):436-43; discussion 436-43. PubMed ID: 15276492
[TBL] [Abstract][Full Text] [Related]
3. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
Puri RK; Hoon DS; Leland P; Snoy P; Rand RW; Pastan I; Kreitman RJ
Cancer Res; 1996 Dec; 56(24):5631-7. PubMed ID: 8971168
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.
Husain SR; Gill P; Kreitman RJ; Pastan I; Puri RK
Mol Med; 1997 May; 3(5):327-38. PubMed ID: 9205948
[TBL] [Abstract][Full Text] [Related]
5. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma.
Kreitman RJ; Bailon P; Chaudhary VK; FitzGerald DJ; Pastan I
Blood; 1994 Jan; 83(2):426-34. PubMed ID: 8286741
[TBL] [Abstract][Full Text] [Related]
6. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.
Kreitman RJ; Puri RK; Pastan I
Cancer Res; 1995 Aug; 55(15):3357-63. PubMed ID: 7614471
[TBL] [Abstract][Full Text] [Related]
7. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity.
Puri RK; Leland P; Obiri NI; Husain SR; Mule J; Pastan I; Kreitman RJ
Cell Immunol; 1996 Jul; 171(1):80-6. PubMed ID: 8660841
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.
Joshi BH; Kawakami K; Leland P; Puri RK
Clin Cancer Res; 2002 Jun; 8(6):1948-56. PubMed ID: 12060640
[TBL] [Abstract][Full Text] [Related]
9. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy.
Husain SR; Behari N; Kreitman RJ; Pastan I; Puri RK
Cancer Res; 1998 Aug; 58(16):3649-53. PubMed ID: 9721874
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.
Kawakami M; Kawakami K; Stepensky VA; Maki RA; Robin H; Muller W; Husain SR; Puri RK
Clin Cancer Res; 2002 Nov; 8(11):3503-11. PubMed ID: 12429641
[TBL] [Abstract][Full Text] [Related]
12. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein.
Joshi BH; Leland P; Silber J; Kreitman RJ; Pastan I; Berger M; Puri RK
Br J Cancer; 2002 Jan; 86(2):285-91. PubMed ID: 11870521
[TBL] [Abstract][Full Text] [Related]
13. Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma.
Ishige K; Shoda J; Kawamoto T; Matsuda S; Ueda T; Hyodo I; Ohkohchi N; Puri RK; Kawakami K
Int J Cancer; 2008 Dec; 123(12):2915-22. PubMed ID: 18798553
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model.
Husain SR; Kreitman RJ; Pastan I; Puri RK
Nat Med; 1999 Jul; 5(7):817-22. PubMed ID: 10395328
[TBL] [Abstract][Full Text] [Related]
15. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.
Kreitman RJ; Hansen HJ; Jones AL; FitzGerald DJ; Goldenberg DM; Pastan I
Cancer Res; 1993 Feb; 53(4):819-25. PubMed ID: 8428363
[TBL] [Abstract][Full Text] [Related]
16. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.
Reiter Y; Brinkmann U; Jung SH; Lee B; Kasprzyk PG; King CR; Pastan I
J Biol Chem; 1994 Jul; 269(28):18327-31. PubMed ID: 7913461
[TBL] [Abstract][Full Text] [Related]
17. Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells.
Kawakami K; Leland P; Puri RK
Cancer Res; 2000 Jun; 60(11):2981-7. PubMed ID: 10850446
[TBL] [Abstract][Full Text] [Related]
18. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.
Reiter Y; Wright AF; Tonge DW; Pastan I
Int J Cancer; 1996 Jul; 67(1):113-23. PubMed ID: 8690511
[TBL] [Abstract][Full Text] [Related]
19. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.
Brinkmann U; Pai LH; FitzGerald DJ; Willingham M; Pastan I
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8616-20. PubMed ID: 1924323
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo studies of antitumor effects of the recombinant immunotoxin MSH-PE38KDEL on melanoma.
Hui Q; Ma J; Song J; Liu Z; Ren H; Jiang W; Wang Y; Xu Y; Guo D; Zhang X; Lu S
Neoplasma; 2014; 61(4):392-400. PubMed ID: 25027740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]